Abstract:Background: Viral resistance to existing inhibitors and the time-dependent effectiveness of neuraminidase inhibitors have limited the number of antivirals that can be used for prophylaxis and therapeutic treatment of severe influenza infection. Thus, there is an urgent need to develop new drugs to prevent and treat influenza infection. Objective: The aim of this study was to design and synthesize a novel series of 2-ureidonicotinamide derivatives, and evaluate their anti-IAV activities. Furthermore, we predicted the abilities of these compounds inhibiting PA-PB1 subunit and forecasted the docking poses of these compounds with RNA polymerase protein (PDB ID 3CM8). Method: The novel designed compounds were synthesized using classical methods of organic chemistry and tested in vitro for their abilities inhibiting RNP and against influenza A virus. In addition, the 23 synthesized molecules were subjected to the generated pharmacophore Hypo1 to forecast the activity target PA-PB1 subunit of RNA polymerase. The ADMET pharmacokinetic parameters were calculated by the ADMET modules in Discovery Studio 2016. The docking results helped us to demonstrate the possible interactions between these compounds with 3CM8. Results: The synthesized 2-ureidonicotinamide derivatives were characterized as potent anti-influenza inhibitors. The target compounds 7b and 7c demonstrated significant antiviral activities, and could be considered as novel lead compounds of antiviral inhibitors. In addition, compound 7b revealed suitable ADME properties expressed, and might be a significant RNA polymerase inhibitor targeting PA-PB1 subunit based on the predictable results and the docking results. Conclusion: This study revealed a novel series of compounds that might be useful in the search for an effective drug against influenza virus.

Chemoreactive-Inspired Discovery of Influenza A Virus Dual Inhibitor to Block Hemagglutinin-Mediated Adsorption and Membrane Fusion.

Design, Synthesis, and Biological Evaluation of Novel Penindolone Derivatives As Potential Inhibitors of Hemagglutinin-Mediated Membrane Fusion.

Design, synthesis, and biological activity of a novel series of 2-ureidonicotinamide derivatives against influenza A virus

Identification of entry inhibitors with 4-aminopiperidine scaffold targeting group 1 influenza A virus

Identification of the Imidazo[1,2- a]pyrazine Derivative A4 as a Potential Influenza Virus Nucleoprotein Inhibitor

Discovery of a Novel Specific Inhibitor Targeting Influenza A Virus Nucleoprotein with Pleiotropic Inhibitory Effects on Various Steps of the Viral Life Cycle

Discovery of Highly Potent Pinanamine-Based Inhibitors Against Amantadine- and Oseltamivir-Resistant Influenza A Viruses.

Discovery of Aryl Benzoyl Hydrazide Derivatives As Novel Potent Broad-Spectrum Inhibitors of Influenza A Virus RNA-Dependent RNA Polymerase (Rdrp)

Optimization of 4-Aminopiperidines As Inhibitors of Influenza A Viral Entry That Are Synergistic with Oseltamivir

Identification of a Novel Inhibitor Targeting Influenza A Virus Group 2 Hemagglutinins.

Design, Synthesis and in Vitro Anti-Influenza A Virus Evaluation of Novel Quinazoline Derivatives Containing S-acetamide and NH-acetamide Moieties at C-4

Design and synthesis of pinane oxime derivatives as novel anti-influenza agents

Design,Synthesis and Anti-influenza Activities of Novel Neuraminidase Inhibitors

Identification of Chebulinic Acid and Chebulagic Acid as Novel Influenza Viral Neuraminidase Inhibitors

Inhibition of influenza A virus replication by a marine derived quinolone alkaloid targeting virus nucleoprotein

Design and Synthesis of 2-((1H-indol-3-yl)thio)-n-phenyl-acetamides As Novel Dual Inhibitors of Respiratory Syncytial Virus and Influenza Virus A.

Discovery of cyperenoic acid as a potent and novel entry inhibitor of influenza A virus

An orally active entry inhibitor of influenza A viruses protects mice and synergizes with oseltamivir and baloxavir marboxil

Synthesis, Optimization, and Structure-Activity Relationships of Imidazo[1,2- a]pyrimidines as Inhibitors of Group 2 Influenza A Viruses

Discovery of ligustrazine and chalcone derivatives as novel viral nucleoprotein nuclear export inhibitors against influenza viruses

Structure-based methoxyflavone derivatives with potent inhibitory activity against various influenza neuraminidases